AU2021259608A1 - Teledermatology system and methods - Google Patents
Teledermatology system and methods Download PDFInfo
- Publication number
- AU2021259608A1 AU2021259608A1 AU2021259608A AU2021259608A AU2021259608A1 AU 2021259608 A1 AU2021259608 A1 AU 2021259608A1 AU 2021259608 A AU2021259608 A AU 2021259608A AU 2021259608 A AU2021259608 A AU 2021259608A AU 2021259608 A1 AU2021259608 A1 AU 2021259608A1
- Authority
- AU
- Australia
- Prior art keywords
- skin
- patient
- teledermatology
- application
- images
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 280
- 238000011156 evaluation Methods 0.000 claims abstract description 169
- 238000012360 testing method Methods 0.000 claims abstract description 112
- 238000005070 sampling Methods 0.000 claims abstract description 63
- 239000000853 adhesive Substances 0.000 claims description 93
- 230000001070 adhesive effect Effects 0.000 claims description 93
- 239000000463 material Substances 0.000 claims description 50
- 230000000977 initiatory effect Effects 0.000 claims description 40
- 238000012552 review Methods 0.000 claims description 40
- 230000004044 response Effects 0.000 claims description 30
- 201000000849 skin cancer Diseases 0.000 claims description 30
- 238000012545 processing Methods 0.000 claims description 25
- 238000004590 computer program Methods 0.000 claims description 22
- 238000003384 imaging method Methods 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 20
- 201000004681 Psoriasis Diseases 0.000 claims description 19
- 238000004422 calculation algorithm Methods 0.000 claims description 15
- 238000013507 mapping Methods 0.000 claims description 15
- 230000003287 optical effect Effects 0.000 claims description 15
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 13
- 201000008937 atopic dermatitis Diseases 0.000 claims description 13
- 230000008833 sun damage Effects 0.000 claims description 13
- 230000002068 genetic effect Effects 0.000 claims description 11
- 230000001973 epigenetic effect Effects 0.000 claims description 10
- 238000009432 framing Methods 0.000 claims description 4
- 238000005286 illumination Methods 0.000 claims description 4
- 230000003902 lesion Effects 0.000 abstract description 103
- 201000001441 melanoma Diseases 0.000 abstract description 38
- 206010040882 skin lesion Diseases 0.000 abstract description 31
- 231100000444 skin lesion Toxicity 0.000 abstract description 31
- 238000003556 assay Methods 0.000 abstract description 19
- 206010028980 Neoplasm Diseases 0.000 abstract description 14
- 238000001514 detection method Methods 0.000 abstract description 14
- 201000011510 cancer Diseases 0.000 abstract description 12
- 230000002757 inflammatory effect Effects 0.000 abstract description 7
- 201000008261 skin carcinoma Diseases 0.000 abstract description 5
- 208000030381 cutaneous melanoma Diseases 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 737
- 239000000523 sample Substances 0.000 description 345
- 239000002390 adhesive tape Substances 0.000 description 100
- 210000001519 tissue Anatomy 0.000 description 96
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 63
- 150000007523 nucleic acids Chemical class 0.000 description 62
- 102000039446 nucleic acids Human genes 0.000 description 61
- 108020004707 nucleic acids Proteins 0.000 description 61
- 210000004027 cell Anatomy 0.000 description 55
- 108090000623 proteins and genes Proteins 0.000 description 55
- 238000003860 storage Methods 0.000 description 45
- 108020004414 DNA Proteins 0.000 description 44
- 230000014509 gene expression Effects 0.000 description 42
- 230000008569 process Effects 0.000 description 28
- 230000001413 cellular effect Effects 0.000 description 27
- 230000000670 limiting effect Effects 0.000 description 27
- 239000011159 matrix material Substances 0.000 description 27
- 208000000453 Skin Neoplasms Diseases 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
- 238000004458 analytical method Methods 0.000 description 21
- 201000010099 disease Diseases 0.000 description 20
- 230000037380 skin damage Effects 0.000 description 19
- 238000004891 communication Methods 0.000 description 18
- 238000012790 confirmation Methods 0.000 description 18
- 210000000434 stratum corneum Anatomy 0.000 description 18
- 230000036541 health Effects 0.000 description 17
- 238000001574 biopsy Methods 0.000 description 15
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 12
- 230000003321 amplification Effects 0.000 description 10
- 238000003199 nucleic acid amplification method Methods 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 239000011324 bead Substances 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 9
- 230000037311 normal skin Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 210000002615 epidermis Anatomy 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 238000010183 spectrum analysis Methods 0.000 description 8
- 230000006378 damage Effects 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 230000033001 locomotion Effects 0.000 description 7
- 230000000813 microbial effect Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 206010004146 Basal cell carcinoma Diseases 0.000 description 6
- 108700011259 MicroRNAs Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 206010025135 lupus erythematosus Diseases 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 230000011218 segmentation Effects 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000003708 edge detection Methods 0.000 description 5
- 210000003128 head Anatomy 0.000 description 5
- 239000002679 microRNA Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 238000003825 pressing Methods 0.000 description 5
- 238000010200 validation analysis Methods 0.000 description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 4
- 208000007256 Nevus Diseases 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000004816 latex Substances 0.000 description 4
- 229920000126 latex Polymers 0.000 description 4
- 210000002752 melanocyte Anatomy 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 238000012502 risk assessment Methods 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 210000000439 stratum lucidum Anatomy 0.000 description 4
- 238000011179 visual inspection Methods 0.000 description 4
- 235000019155 vitamin A Nutrition 0.000 description 4
- 239000011719 vitamin A Substances 0.000 description 4
- 229940045997 vitamin a Drugs 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 208000012641 Pigmentation disease Diseases 0.000 description 3
- -1 RNA or DNA Chemical class 0.000 description 3
- 208000006981 Skin Abnormalities Diseases 0.000 description 3
- 206010064127 Solar lentigo Diseases 0.000 description 3
- 108020004566 Transfer RNA Proteins 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 238000012854 evaluation process Methods 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 206010024217 lentigo Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000004973 liquid crystal related substance Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000003071 parasitic effect Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 210000000437 stratum spinosum Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- VSKJLJHPAFKHBX-UHFFFAOYSA-N 2-methylbuta-1,3-diene;styrene Chemical group CC(=C)C=C.C=CC1=CC=CC=C1.C=CC1=CC=CC=C1 VSKJLJHPAFKHBX-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 229920001621 AMOLED Polymers 0.000 description 2
- 208000002782 Acneiform Eruptions Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000022715 Autoinflammatory syndrome Diseases 0.000 description 2
- 102100038504 Cellular retinoic acid-binding protein 2 Human genes 0.000 description 2
- 108091028075 Circular RNA Proteins 0.000 description 2
- 208000000471 Dysplastic Nevus Syndrome Diseases 0.000 description 2
- 206010062805 Dysplastic naevus Diseases 0.000 description 2
- 206010061217 Infestation Diseases 0.000 description 2
- 206010024218 Lentigo maligna Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 206010027145 Melanocytic naevus Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 102000039471 Small Nuclear RNA Human genes 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 208000002352 blister Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004883 computer application Methods 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 238000010228 ex vivo assay Methods 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 230000003118 histopathologic effect Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 108010075526 keratohyalin Proteins 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 238000013188 needle biopsy Methods 0.000 description 2
- 208000004649 neutrophil actin dysfunction Diseases 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- APTZNLHMIGJTEW-UHFFFAOYSA-N pyraflufen-ethyl Chemical compound C1=C(Cl)C(OCC(=O)OCC)=CC(C=2C(=C(OC(F)F)N(C)N=2)Cl)=C1F APTZNLHMIGJTEW-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 150000004492 retinoid derivatives Chemical class 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 108020004418 ribosomal RNA Proteins 0.000 description 2
- 238000010079 rubber tapping Methods 0.000 description 2
- 239000010979 ruby Substances 0.000 description 2
- 229910001750 ruby Inorganic materials 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 108091029842 small nuclear ribonucleic acid Proteins 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 210000000498 stratum granulosum Anatomy 0.000 description 2
- 230000036561 sun exposure Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 239000012780 transparent material Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 108050008825 Cellular retinoic acid-binding protein 2 Proteins 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 208000008334 Dermatofibrosarcoma Diseases 0.000 description 1
- 206010057070 Dermatofibrosarcoma protuberans Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000019872 Drug Eruptions Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000006004 Flea Infestations Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 240000000594 Heliconia bihai Species 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 101001099851 Homo sapiens Cellular retinoic acid-binding protein 2 Proteins 0.000 description 1
- 208000029966 Hutchinson Melanotic Freckle Diseases 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 208000005995 Lichenoid Eruptions Diseases 0.000 description 1
- 206010025652 Malignant melanoma in situ Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 206010027626 Milia Diseases 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- 206010029488 Nodular melanoma Diseases 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 206010033554 Palmoplantar keratoderma Diseases 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 208000009077 Pigmented Nevus Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101710136733 Proline-rich protein Proteins 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 206010042553 Superficial spreading melanoma stage unspecified Diseases 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 108091046869 Telomeric non-coding RNA Proteins 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 241000726445 Viroids Species 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000583 acral lentiginous melanoma Diseases 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 238000011511 automated evaluation Methods 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 108091092259 cell-free RNA Proteins 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000002777 columnar cell Anatomy 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 108050004038 cystatin Proteins 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- VJYFKVYYMZPMAB-UHFFFAOYSA-N ethoprophos Chemical compound CCCSP(=O)(OCC)SCCC VJYFKVYYMZPMAB-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000024711 extrinsic asthma Diseases 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000001329 hyperkeratotic effect Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000013394 immunophenotyping Methods 0.000 description 1
- 238000002847 impedance measurement Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 208000011080 lentigo maligna melanoma Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 208000028138 melanocytic neoplasm Diseases 0.000 description 1
- 201000002699 melanoma in congenital melanocytic nevus Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 201000002266 mite infestation Diseases 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000010241 mucinoses Diseases 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 230000006855 networking Effects 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 201000000032 nodular malignant melanoma Diseases 0.000 description 1
- 238000001821 nucleic acid purification Methods 0.000 description 1
- 230000001293 nucleolytic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 108091007428 primary miRNA Proteins 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 201000007321 sebaceous carcinoma Diseases 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000005005 sentinel lymph node Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 239000010454 slate Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000000438 stratum basale Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 208000030457 superficial spreading melanoma Diseases 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
- A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
- A61B5/444—Evaluating skin marks, e.g. mole, nevi, tumour, scar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
- A61B5/0004—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by the type of physiological signal transmitted
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
- A61B5/0015—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by features of the telemetry system
- A61B5/0022—Monitoring a patient using a global network, e.g. telephone networks, internet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0077—Devices for viewing the surface of the body, e.g. camera, magnifying lens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient; User input means
- A61B5/742—Details of notification to user or communication with user or patient; User input means using visual displays
- A61B5/744—Displaying an avatar, e.g. an animated cartoon character
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient; User input means
- A61B5/7465—Arrangements for interactive communication between patient and care services, e.g. by using a telephone network
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H30/00—ICT specially adapted for the handling or processing of medical images
- G16H30/40—ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H80/00—ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Computer Networks & Wireless Communication (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Nursing (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Sampling And Sample Adjustment (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063014057P | 2020-04-22 | 2020-04-22 | |
| US63/014,057 | 2020-04-22 | ||
| US202063106806P | 2020-10-28 | 2020-10-28 | |
| US63/106,806 | 2020-10-28 | ||
| PCT/US2021/028415 WO2021216721A1 (en) | 2020-04-22 | 2021-04-21 | Teledermatology system and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021259608A1 true AU2021259608A1 (en) | 2022-11-17 |
Family
ID=78221047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021259608A Abandoned AU2021259608A1 (en) | 2020-04-22 | 2021-04-21 | Teledermatology system and methods |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210330245A1 (https=) |
| EP (1) | EP4138677A4 (https=) |
| JP (1) | JP2023522952A (https=) |
| AU (1) | AU2021259608A1 (https=) |
| BR (1) | BR112022021282A2 (https=) |
| CA (1) | CA3177608A1 (https=) |
| MX (1) | MX2022013155A (https=) |
| WO (1) | WO2021216721A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102089444A (zh) | 2008-05-14 | 2011-06-08 | 德玛泰克国际公司 | 利用核酸分析方法来诊断黑素瘤和太阳能雀斑 |
| WO2023220745A2 (en) * | 2022-05-13 | 2023-11-16 | Dermtech, Inc. | Novel expression based, non-invasive method to differentiate atopic dermatitis and psoriasis |
| US10709428B2 (en) * | 2015-05-01 | 2020-07-14 | Dermtech, Inc. | Non-invasive skin collection system |
| WO2018156809A1 (en) * | 2017-02-24 | 2018-08-30 | Masimo Corporation | Augmented reality system for displaying patient data |
| JP7159208B2 (ja) | 2017-05-08 | 2022-10-24 | マシモ・コーポレイション | ドングルを使用することによって医療システムをネットワークコントローラとペアリングするためのシステム |
| CA3090785A1 (en) | 2018-02-14 | 2019-08-22 | John Daniel Dobak Iii | Novel gene classifiers and uses thereof in non-melanoma skin cancers |
| JP2022524641A (ja) | 2019-03-26 | 2022-05-09 | ダームテック，インク． | 皮膚癌における新規な遺伝子分類子とその使用 |
| KR102748064B1 (ko) * | 2022-05-12 | 2024-12-31 | 연세대학교 산학협력단 | 연조직 질환 감별 방법, 및 이를 포함하는 장치 |
| WO2023235628A1 (en) * | 2022-06-03 | 2023-12-07 | University Of Central Florida Research Foundation, Inc. | System to visualize, measure and track skin abnormalities |
| KR20240066530A (ko) | 2022-11-07 | 2024-05-16 | 스페클립스 주식회사 | 인공지능을 이용한 이미지 분석 기반 피부암 진단 방법 |
| USD1061554S1 (en) | 2022-09-09 | 2025-02-11 | Dermtech, Llc | Computer display panel with a graphical user interface for a dermatology report |
| WO2024191957A1 (en) * | 2023-03-10 | 2024-09-19 | Castle Biosciences, Inc. | Diagnosing and treating atopic dermatitis, psoriasis, and/or mycosis fungoides |
| EP4459626A1 (en) * | 2023-05-04 | 2024-11-06 | Siemens Healthineers AG | Method of adjudicating an imaged lesion |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3717789B2 (ja) * | 2001-02-02 | 2005-11-16 | 富士通株式会社 | 通信システムおよび情報仲介方法並びに記録媒体 |
| US20060111620A1 (en) * | 2004-11-23 | 2006-05-25 | Squilla John R | Providing medical services at a kiosk |
| KR20090097904A (ko) * | 2007-01-05 | 2009-09-16 | 마이스킨 인크 | 피부 이미징을 위한 시스템, 디바이스 및 방법 |
| US8358348B2 (en) * | 2008-05-09 | 2013-01-22 | Elc Management Llc | Method and system for automatic or manual evaluation to provide targeted and individualized delivery of cosmetic actives in a mask or patch form |
| CA2734521A1 (en) * | 2008-08-28 | 2010-03-04 | Dermtech International | Determining age ranges of skin samples |
| US20110040571A1 (en) * | 2009-08-14 | 2011-02-17 | Felicity Warren | System and method for providing for teledermatology |
| US8700432B2 (en) * | 2010-03-19 | 2014-04-15 | Gary A. Letts | Method and system for cutaneous medicine diagnostics |
| JP5474663B2 (ja) * | 2010-05-28 | 2014-04-16 | 第一三共ヘルスケア株式会社 | 肝斑判断支援システム |
| AU2012312170C1 (en) * | 2011-09-21 | 2018-01-04 | Shiseido Company, Ltd. | Compositions and methods for treating conditions of compromised skin barrier function |
| TWI556116B (zh) * | 2012-02-15 | 2016-11-01 | Hitachi Maxell | Skin condition analysis and analysis information management system, skin condition analysis and analysis information management method, and data management server |
| TWI493169B (zh) * | 2013-01-18 | 2015-07-21 | Univ Nat Cheng Kung | 評估皮膚生理參數濃度及分布之光學系統及其方法 |
| WO2015029452A1 (ja) * | 2013-08-30 | 2015-03-05 | 株式会社ニュートリション・アクト | 解析装置、解析方法、プログラム、および肌サンプル採取キット |
| US9538610B2 (en) * | 2014-04-14 | 2017-01-03 | Osram Sylvania Inc. | Circuits for phase-cut analog dimming of solid state light sources |
| US10709428B2 (en) * | 2015-05-01 | 2020-07-14 | Dermtech, Inc. | Non-invasive skin collection system |
| EP3294106B1 (en) * | 2015-05-12 | 2020-08-26 | Zipline Health, Inc. | Devices for acquiring medical diagnostic information and provision of telehealth services |
| US10415105B2 (en) * | 2015-06-30 | 2019-09-17 | uBiome, Inc. | Method and system for diagnostic testing |
| US20170329929A1 (en) * | 2016-05-11 | 2017-11-16 | Sensus Healthcare Llc | Virtual pathology for dermatology |
| DE102016006196A1 (de) * | 2016-05-19 | 2017-11-23 | Biomedatronik UG (haftungsbeschränkt) | Innovatives verfahren und multisensor-plattform zum nichtinvasiven monitoring von physiologischen parameter und blutinhaltstoffe sowie frühdiagnose der pathologischen änderungen und gesundheits-management und ihre anwendung mit smartphone |
| WO2018081297A1 (en) * | 2016-10-25 | 2018-05-03 | Thomas Jefferson University | Telehealth systems |
| JP6256779B2 (ja) * | 2016-12-06 | 2018-01-10 | ソニー株式会社 | 情報処理装置、情報処理方法、プログラム、及び測定システム |
| US10354383B2 (en) * | 2016-12-30 | 2019-07-16 | Skinio, Llc | Skin abnormality monitoring systems and methods |
| US11854200B2 (en) * | 2016-12-30 | 2023-12-26 | Skinio, Inc. | Skin abnormality monitoring systems and methods |
| KR102581945B1 (ko) * | 2017-02-07 | 2023-09-25 | 삼성전자주식회사 | 스킨 정보 제공 방법 및 이를 지원하는 전자 장치 |
| US20190214116A1 (en) * | 2018-01-10 | 2019-07-11 | Cheryl Lee Eberting | Digital health platform for chronic disease management, secure messaging, prescription management, and integrated e-commerce curation |
| JP6686223B1 (ja) * | 2019-10-24 | 2020-04-22 | 株式会社アイム | 肌状態評価方法 |
-
2021
- 2021-04-21 US US17/236,919 patent/US20210330245A1/en not_active Abandoned
- 2021-04-21 BR BR112022021282A patent/BR112022021282A2/pt unknown
- 2021-04-21 JP JP2022564109A patent/JP2023522952A/ja active Pending
- 2021-04-21 AU AU2021259608A patent/AU2021259608A1/en not_active Abandoned
- 2021-04-21 CA CA3177608A patent/CA3177608A1/en active Pending
- 2021-04-21 WO PCT/US2021/028415 patent/WO2021216721A1/en not_active Ceased
- 2021-04-21 EP EP21792502.3A patent/EP4138677A4/en not_active Withdrawn
- 2021-04-21 MX MX2022013155A patent/MX2022013155A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3177608A1 (en) | 2021-10-28 |
| MX2022013155A (es) | 2022-11-16 |
| US20210330245A1 (en) | 2021-10-28 |
| EP4138677A4 (en) | 2024-08-07 |
| WO2021216721A1 (en) | 2021-10-28 |
| JP2023522952A (ja) | 2023-06-01 |
| EP4138677A1 (en) | 2023-03-01 |
| BR112022021282A2 (pt) | 2022-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210330245A1 (en) | Teledermatology system and methods | |
| Coustasse et al. | Use of teledermatology to improve dermatological access in rural areas | |
| van Netten et al. | The validity and reliability of remote diabetic foot ulcer assessment using mobile phone images | |
| Mackillop et al. | Development of a real-time smartphone solution for the management of women with or at high risk of gestational diabetes | |
| Yaraghi | An empirical analysis of the financial benefits of health information exchange in emergency departments | |
| JP2022518364A (ja) | 医療病状を評価するための画像分析の使用 | |
| KR101720040B1 (ko) | 하나 이상의 생물학적 테스트 대상들 또는 환경 테스트 대상들과 관련된 수집된 데이터 및 분석된 데이터를 저장하고, 분석하고, 이들 데이터에 대한 액세스를 가능하게 하는 방법 및 시스템 | |
| US20120179478A1 (en) | Devices, Systems, and Methods for the Real-Time and Individualized Prediction of Health and Economic Outcomes | |
| US20230035208A1 (en) | Clinical trial/patient follow-up platform | |
| Elson et al. | The Athena Breast Health Network: developing a rapid learning system in breast cancer prevention, screening, treatment, and care | |
| Cappon et al. | AGATA: a toolbox for automated glucose data analysis | |
| Marsden et al. | Accuracy of an artificial intelligence as a medical device as part of a UK-based skin cancer teledermatology service | |
| Li et al. | How does the artificial intelligence-based image-assisted technique help physicians in diagnosis of pulmonary adenocarcinoma? A randomized controlled experiment of multicenter physicians in China | |
| CN106999041B (zh) | 用于健康相关问题的管理的智能记录 | |
| Bower et al. | Active use of electronic health records (EHRs) and personal health records (PHRs) for epidemiologic research: sample representativeness and nonresponse bias in a study of women during pregnancy | |
| US20230124917A1 (en) | Systems and methods for monitoring and identifying physiological impact events | |
| Hao et al. | A prospective cohort study on the management of young patients with newly diagnosed type 2 diabetes using mobile medical applications | |
| Balakrishnan et al. | A mobile health intervention for prostate biopsy patients reduces appointment cancellations: cohort study | |
| Kivity et al. | Optimising wound monitoring: Can digital tools improve healing outcomes and clinic efficiency | |
| Lindberg et al. | ERegTime, efficiency of health information management using an electronic registry for maternal and child health: Protocol for a time-motion study in a cluster randomized trial | |
| Xu et al. | Diabetes technology meeting 2021 | |
| Ayatollahi | Point-of-care diagnostics with smartphone | |
| Jozic et al. | Flipping the script: are cellular assays and wound fluids the next frontier in personalized wound care? | |
| Koinberg et al. | A health economic evaluation of follow-up after breast cancer surgery: results of an rct study | |
| Dempsey et al. | The High Price of Equity in Pulse Oximetry: A cost evaluation and need for interim solutions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |